[Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles].
A new dosage formulation (ACR-CH), composed of aclarubicin (ACR) bound to fine activated carbon particles, was developed for the treatment of lymph node metastases in patients with breast cancer. In a mice experimental model, ACR-CH had superior therapeutic effects on lymph node metastases compared to the same dose of ACR aqueous solution. In clinical trials, patients with breast cancer received a local injection of 10 mg/person of ACR in the form of ACR-CH or ACR aqueous solution just before mastectomy. In the regional lymph nodes removed by the operation, the ACR concentration of 40.7 micrograms/g in patients given ACR-CH was higher than the 25.1 micrograms/g in patients given ACR aqueous solution, whereas in blood plasma the concentration was higher in patients given ACR aqueous solution than in those given ACR-CH.
Imanishi
T
T
First Dept. of Surgery, Kyoto Prefectural University of Medicine.
Sakakibara
T
T
Yamazaki
J
J
Ohyama
T
T
Shirasu
M
M
Tsujimoto
H
H
Ohgaki
M
M
Shimotsuma
M
M
Hagiwara
A
A
Sawai
K
K
D015250:Aclarubicin / Q000008:administration & dosage*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D002244:Carbon; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007941:Leukemia P388 / Q000188:drug therapy / Q000473:pathology; D008207:Lymphatic Metastasis; D008408:Mastectomy; D051379:Mice
D000903:Antibiotics, Antineoplastic; D003692:Delayed-Action Preparations; D002244:Carbon; D015250:Aclarubicin